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Automating Gene Editing Using Digital Microfluidics 




Gene-editing techniques such as RNA-guided endonuclease systems are becoming increasingly 
popular for phenotypic screening.  Such screens are normally conducted in arrayed or pooled 
formats.  There has been considerable interest in recent years to find new technological methods 
for conducting these gene-editing assays.  We report here the first digital microfluidic method that 
can automate arrayed gene-editing in mammalian cells. Functional microfluidic devices were 
designed and optimized to produce repeatable experiments and validate the relevant biological 
processes on device.  Specifically, this method was useful in culturing lung cancer cells for up to 
six days, as well as implementing automated gene transfection and knockout procedures.  In 
addition, a standardized imaging pipeline to analyse fluorescently labelled cells was also designed 
and implemented during these procedures.  A gene editing assay for interrogating the MAPK/ERK 
pathway was performed to show the utility of our platform and to determine the effects of knocking 
out the RAF1 gene in lung cancer cells.  In addition to gene knockout, we also treated the cells 
with an inhibitor, Sorafenib Tosylate, to determine the effects of enzymatic inhibition.  The 
combination of enzymatic inhibition and guide targeting on device resulted in lower drug 
concentrations for achieving half-inhibitory effects (IC50) compared to cells treated only with the 
inhibitor, confirming that lung cancer cells are being successfully edited on the device.  We 
propose that this system will be useful for other types of gene-editing assays and applications 
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Overview of Chapters 
 
This thesis describes the project I conducted and completed for my Master’s in Applied 
Science in Dr. Steve Shih’s research group at Concordia University. In this work, I aimed to 
develop a fully-automated digital microfluidic platform tailored to CRISPR-Cas9 genome editing 
in cancer cells, for systematic loss-of-function screens. This thesis provides a literature review on 
the history of miniaturization and microfluidic paradigms, an in-depth review of digital 
microfluidics and a commentary on the state of gene editing techniques while assessing the 
technological challenges in operating CRISPR-Cas9. I will then get into the core of my research, 
reporting the methodology utilized for the development of an intuitive gene editing platform, and 
validating the platform with experimental results.  
Chapter 1 is an introduction to microfluidics within the bigger realm of miniaturization, describing 
the three dominant paradigms and briefly evaluating their potential for cell-based applications. 
From this review, we will draw a table comparing the three paradigms. 
Chapter 2 provides an in-depth review of digital microfluidics theory, venting its merits as a 
versatile liquid handling platform, describes the fabrication methods, assess the potential for 
automation and finally comments on its amenability to cell culture. 
Chapter 3 is a review of the biological stakes that we will be addressing with our platform, 
presenting gene editing techniques with a special focus on CRISPR-Cas9 in the context of cancer 
research, and comments on the technological limitations in operating CRISPR-Cas9 today. This 
commentary will lead to the presentation of my thesis objectives. 
Chapter 4 provides a complete description of my methods, both on the biology and engineering 
side, to develop a functional gene editing system.  
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Chapter 5 describes my results in validating the gene editing platform. I will describe the device 
design optimization, the validation of the platform for transfection of nucleic acid, proof-of-
concept work for knock-out of endogenous genes and applying our platform to study cell 
proliferation. 
Chapter 6 provides concluding remarks regarding my work and its potential in clinical research. I 
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Digital microfluidics (DMF) is a technology that provides a means of manipulating nL-L 
volumes of liquids on an array of electrodes. By applying an electric potential to an electrode, 
these discrete droplets can be controlled in parallel which can be transported, mixed, reacted, and 
analyzed. Typically, an automation system is interfaced with a DMF device uses a standard set of 
basic instructions written by the user to execute droplet operations. Here, we present the first 
feedback method for DMF that relies on imaging techniques that will allow online detection of 
droplets without the need to reactivate all destination electrodes while minimizing the biofouling 
within a given experiment. Our system consists of integrating open-source electronics with a 
CMOS camera with a zoom lens for acquisition of the droplet movements on the device. We also 
created an algorithm that uses a Hough transform to detect a variety of droplet sizes and to detect 
singular droplet dispensing and movement failures on the device.  As a first test, we applied this 
feedback system to testing the droplet movement of a variety of liquids used in cell-based assays 
and implemented a colorimetric cellulase assay to determine enzymes suitable for breaking down 
biomass for biofuel production.  We believe using our approach of integrating imaging and 
feedback with DMF can provide a platform for automating biological assays with high-fidelity. 
Vo, P.Q.N., Husser, M.C., Ahmadi, F., Sinha, H. & Shih, S.C.C. Image-based feedback and 
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The expression of a recombinant gene in a host organism through induction can be an extensively 
manual procedure.  Several methods have been developed to simplify the protocol, but none has 
fully replaced the traditional IPTG-based induction.  To simplify this process, we describe the 
development of an auto-induction platform based on digital microfluidics.  This system consists 
of a 600 nm LED and a light sensor to enable the real-time monitoring of samples optical density 
(OD) coordinated with the semi-continuous mixing of a bacterial culture.  A hand-held device was 
designed as a micro-bioreactor to culture cells and to measure the OD of the bacterial culture.  In 
addition, it serves as a platform for the analysis of regulated protein expression in E.coli without 
the requirement of standardized well-plates or pipetting-based platforms.  Here, we report for the 
first time, a system that offers great convenience without the user to physically monitor the culture 
or to manually add inducer at specific times.  We characterized our system by looking at several 
parameters (electrode designs, gap height, and growth rates) required for an auto-inducible system.  
As a first step, we carried out an automated induction assay on a RFP reporter gene to identify 
conditions suitable for our system.  Next, we used our system to identify active thermophilic -
glucosidase enzymes which may be suitable candidates for biomass hydrolysis.  Overall, we 
believe that this platform may be useful for synthetic biology applications that require regulating 
and analyzing expression of heterologous genes. 
Husser, M.C., Vo, P.Q.N., Sinha, H., Ahmadi, F. & Shih, S.C.C. An Automated Induction 
Microfluidics System for Synthetic Biology. ACS Synth Biol 7, 933-944 (2018). 
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Chapter 1. Introduction to Miniaturized Fluid Handling 
 
In this section, we will introduce microfluidics in the bigger realm of miniaturization, 
describe the three dominant paradigms and briefly evaluate their potential for cell-based 
applications. From this review, we will draw a table comparing the three paradigms. 
 
1.1 Historical Perspectives on the Miniaturization of Biology 
Biologists first began shifting away from traditional glass tubes and dishes for bench-top 
biology in the 1950s when Dr. G. Takatsy described the first microtiter well-plates. 1 The invention 
of multi-well plates led to an unprecedented increase in throughput, having a number of wells with 
predefined volumetric capacities in the range of microliters to milliliters arranged in a 
standardized, rectangular matrix. Takatsy laid the foundations for early bench-top miniaturization 
and his contemporary counterparts still resort to such methods for high-throughput drug screening, 
enzymatic assays, cell-based assays, and countless other applications.  
Towards the end of the twentieth century, high-throughput screening (HTS) became the 
gold standard for pharmaceutical drug discovery, where the limits of throughput and screening 
efficiency were stretched by creating new 384- and 1536-well formats. Such formats enabled 
higher experimental densities in parallel with lower experimental footprints due to reduced reagent 
consumptions along with higher statistical significance with facilitated experiment replication. 
HTS is now actively used in a wide-range of applications, from genomics to environmental 
sampling and from protein crystallization to cell-based assays.  
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HTS requires cutting-edge technologies at high precision to keep up with the number of 
samples being assayed in parallel, at a pace that is unachievable by manual labor. In the past few 
decades, automated liquid handling robotics (ALHR) have been developed to automate fluid 
handling and facilitate the handling of large numbers samples in microtiter plates. Despite the 
groundbreaking technological advances in such systems, robotics is often inaccessible given the 
high capital costs (can reach a few million USD), the excessive consumption of consumables 
(pipette tips, multi-well plates, etc.) and large volumes of reagents being consumed (media, drugs, 
cells, etc.). Attention is slowly shifting towards cheaper alternatives for biology miniaturization 
and automation, with higher content and quality of the data.  
As progress was being made in miniaturizing benchtop experiments into microtiter plates, 
significant progress was being made in understanding fluid dynamics, notably Brownian motion 
and diffusion, by the combined efforts from Einstein2 and Berg3 in biological systems. In parallel, 
Taylor4 had been examining liquid flow in micron-scale channels. The development of 
miniaturized chromatographic5 and ink-jet technologies6 enabled the innovation and 
implementation of “microfluidics” for biological investigation. Furthermore, the development of 
soft-lithography, solid etching and replica molding in PDMS, presented by the Whitesides group 
in 1998,7 led to the popularization of microfluidic technologies. Microfluidic technologies are 
being extensively explored as an alternative to multi-well plates and led to the development of 
numerous technologies vulgarized as “labs-on-a-chip” (LOC) technologies.  
LOC technologies are characterized by a miniaturization of experiments and integration of 
laboratory instruments onto tiny hand-held devices. With simple and cheap fabrication procedures, 
and handling of small volumes and samples, such devices bypass the need for expensive operating 
systems, and enable high-throughput and automation. Three paradigms have emerged and become 
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dominant in the midst of miniaturization. The first is microchannels, being the most popular 
paradigm, where bulk fluid flows through micron-sized dimension channels.8, 9 The second is 
droplets-in-channel, where fluid is manipulated as discrete droplets in enclosed channels, where 
each droplet acts as an individual microreactor.10, 11 Finally, digital microfluidics (DMF) is the 
manipulation of fluids as discrete droplets on an open array of electrodes.12-14 I will briefly review 
all of these paradigms before venting the merits of DMF as a versatile liquid handling platform. 
 
1.2 Microchannels 
The most widespread form of microfluidics today is microchannels, also known as 
continuous channel microfluidics, where micron-sized dimension channels confine reagents. The 
liquid transport of such reagents is driven by pressure gradients from external (e.g. syringe pumps) 
or internal pressure sources. Fluid flow is enabled after injection of reagents into the chip either 
batch-wise or in continuous mode. In these systems, the flow is dependent on two conflicting 
forces: (1) inertia, the resistance of objects to changing their current state of motion and (2) 
viscosity, i.e. the resistance of a fluid to stress-induced deformations. The balance of these two 
forces is described by the dimensionless Reynold’s number: 
 








where ρ is the fluid density (kg/m3), v is the mean velocity (m/s), L is the characteristic length of 
the system, and υ is the kinematic viscosity (m2/s).  
The dominance of one of these two forces over the other will determine whether the flow 
is turbulent (chaotic) or laminar (deterministic). When Re < 2000, the flow is laminar, when 2000 
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< Re < 4000, the flow is unstable and when Re > 4000, the flow is turbulent. Given the micron-
size of these channels, the length can be estimated to around 10-6 m – this results in most 
microfluidic systems to be viscosity dominated, resulting in laminar flows with low Reynold’s 
number regimes. Such laminar flow enables multiple streams of reagents to be constrained within 
a single channel without mixing.   
Such a technology has been used in numerous biological applications, including chemical 
separations,15 single cell/molecule analysis,16 and simple reactions performing better at the 
microscale with high surface-to-volume ratio.17  The surface area to volume ratio increases when 
the scale of volumes is reduced. This substantially increases heat and mass transfer rates, useful to 
speed up exothermic and endothermic reactions. The integration of microvalves relying on flexible 
membranes and pneumatic control layers on-device allows these devices to become 
compartmentalized high-throughput systems.8, 18-20 Such compartmentalization enables 
multiplexing, by which ~ 106 independent compartments are formed, each containing volumes in 
the range of 10-100 picoliters.18 Nevertheless, microvalves require complex fabrication techniques 
(1 compartment requires at least 1 valve) and precise alignment strategies to make a functional 
device. In addition, the number of inlets and external pressure sources such as syringe pumps 
increases the complexity in fabrication, costs, manual intervention and expertise. Such inherently 
complex fabrication techniques, coupled to the dependence on external equipment and complex 
tubing/device assembly often makes microchannels undesirable to implement in the daily 
workflows of biologists. In addition, the inability to efficiently mix reagents limits the breadth of 





The droplets-in-channel paradigm is characterized by a two-phase flow, usually with water, 
oil and/or gas, in microchannels. Such a configuration enables the formation of pico and nano-liter 
droplets, that can be generated at rates in the thousands of droplets per second. These droplets can 
be merged, sorted and reacted on-demand.10, 21, 22 Such devices are simple to fabricate and can 
operate at high-throughput (10-100 kHz) which makes them desirable for biological screening 
applications. Research and development in this field has been increasing control over individual 
droplets, for better in-channel guiding and sorting using rails,23-25 laser forcing,26 or electrostatic 
charging. 27-29 
The most significant advantages of such a miniaturized platform is the small size of 
working volumes, the high-throughput nature of reagent manipulation, the individuality of each 
droplet eliminating the risk of cross-contamination, different strategies to mix reagents within 
droplets and the ability to incubate and store these miniscule droplets for extended periods of time 
without evaporation. Bio-compatible surfactants are often used to stabilize emulsions, which 
allows live cells to be encapsulated, and fluorinated oils in the continuous phase allows sufficient 
gas exchanges to maintain cell viability for extended periods of time. Such advantages have 
garnered interest in numerous fields and applications, including magnetic-bead based assays,30-32 
single cell high-throughput studies,33-35 protein crystallization36 and chemical synthesis.37  
Nevertheless, just like microchannels, droplet microfluidics requires pumps, complex 
tubing for inlets and outlets and other external equipment, which discourages certain researchers 
to move away from their traditional practices. Also, multi-step long-term applications are difficult 
to implement in such systems given that the speed of individual droplets makes the individual 
addressability of droplets complicated for reagent addition, staining and media exchange. 
6 
 
Furthermore, sorting and detection often requires optical systems and read-outs, and specialized 
microscopy analysis techniques, thereby complicating the process.   
 
1.4 Digital Microfluidics 
My research utilized a more recent technology developed in the realm of miniaturization 
called digital microfluidics (DMF), still in its infancy. Such a technology accurately represents the 
“lab-on-a-chip mindset”, where all laboratory instruments and components are integrated onto a 
single hand-held device. The technology relies on the manipulation of picoliter-milliliter sized 
droplets on an array of electrodes. DMF is now being used in a wide-range of applications, with 
the advantages of reduced sample size, fast heat transfer and reduced reaction rates (explained by 
the high surface area to volume ratio) and is highly amenable to integration. A wide range of 
operations can be performed and reprogrammed on-demand, such as dispensing droplets from 
reservoirs, moving, merging, mixing and splitting into smaller droplets. One of the key advantages 
is that droplets can be addressed individually, where each reagent operated on a DMF device is 
isolated until merged with another reagent, and with each droplet acting as a discrete microvessel 
with no cross-talk with neighboring samples. Microchannels are very different in that respect 
where they operate with conventional flow and may be disturbed by hydrostatic and capillary 
flows. In addition, DMF devices are operated on generic platforms with simple configurations (M 
x N array), making them easy to operate and to reconfigure.  
The individual addressability of samples makes DMF an inherently array-based technique. 
This makes DMF ideal for array-based biochemical applications. Despite certain challenges and 
disadvantages of DMF, we sought to harness the platform to automate gene editing, given that 
DMF allows a rational design approach to be used to target certain specific genes in an arrayed 
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manner, where experiments can be multiplexed and reprogrammed, cell-based assays can be 




Figure 1.1 – Microfluidic Paradigms.  
(a) Microchannels. Reproduced with permission from the Royal Society of Chemistry.38                        
(b) Droplets-in-channel. Reproduced with permission from the Royal Society of Chemistry.39            






1.5 Summary Table of Microfluidic Technologies 
We hereby present a comparative table (Table 1.1) showing the state of microfluidic 
techniques versus traditional sampling in multiwell plates and show the advantages that each of 
these solutions offer in the market of miniaturization.  
 
Table 1.1 – Comparative table assessing the state of miniaturization techniques. 











Reagent volume μL-mL nL-μL pL-nL 100 pL-mL 
Throughput High Moderate High Low 
Automation ++ + + +++ 
Reprogramming + + + +++ 
External Parts Robotics Pumps & valves Pumps & valves None 
Temperature 
Control 












No. of Scientists 
in the Field 




Chapter 2. Special Focus on Digital Microfluidics 
 
This chapter will provide an in-depth review of DMF theory, venting its merits as a 
versatile liquid handling platform, describe the fabrication methods, assess the potential for 
automation and finally comment on its amenability to cell culture. 
 
2.1 Digital Microfluidic Theory 
In the broad realm of biomimicry, scientists have been eager to control the surface 
wettability by fluids, in a similar way that nature has engineered “self-cleaning” lotus leaves or 
“fog-collecting” Stenocara beetle.14 From this research drive emerged a phenomenon known as 
“electrowetting”, by which a solid surface’s wettability can be altered using electric potential.40-42  
Electrowetting-on-dielectric (EWOD) is a phenomenon that can be applied to control aqueous 
liquids by varying the electric energy across the micron-thick dielectric layer separating the liquid 
and the conducting substrate.42 This phenomenon can be translated to a driving mechanism, where 
liquids can be shaped and driven along a path of electrodes. Fluid position can therefore be 
modulated by placing droplets on an array of electrodes coated with an insulator.14 Electrical 
potential can be applied sequentially to adjacent electrodes on a path, and the droplets carrying 
various reagents can be moved on that array on-demand. 
The reigning forces in EWOD can be separated into driving and resistive forces. The 
earliest theoretical attempts for estimating the driving forces were based on a thermodynamic 





Equation 2.1: Young-Lippman Equation 






where θw and θ0 are the wetted and static contact angles, respectively; ε0 and εr are the permittivities 
of free space and of the dielectric, respectively; V is the applied voltage; γ is the liquid/filler media 
surface tension (air or oil); and t is the dielectric thickness. In this model, it is assumed that droplets 
are moved due to capillary pressure resulting from asymmetric contact angles across the droplet. 
In Equation 2.1, the contact angles are static and do not account for droplet motion after 
deformation. Therefore, the driving force F in this model can be expressed as: 
 
Equation 2.2: Driving force using Young-Lippman 






where F is the driving force and L is the length of the contact line overlapping the actuated 
electrode. This driving force is often referred to as the “EWOD force”.  
The term “Digital Microfluidics” emerged upon the realization that the theory behind 
electrowetting does not apply to fluids with low surface tension, given that such liquids are readily 
moved on electrodes but do not exhibit a significant change in contact angle – this empirical result 
showed that large changes in contact angles are not a requirement for droplet movement. In 
addition, the thermodynamic approach fails to explain the liquid-dielectrophoretic force, which is 
predominant at high frequencies.  
In fact, the wetting is an observable effect of the forces acting on the droplet. The most 
accurate way to estimate the forces on the droplet in DMF is to use a circuit diagram and adopting 
an electromechanical approach. The amount of energy stored in this system is calculated as a 
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function of the applied voltage frequency and droplet position along the direction of translation. 
Here is the Equation 2.3 representing the amount of energy, E, of the system: 
 
Equation 2.3: Energy equation using electromechanical model 














where L is the dimension of the droplet (estimated by the cross-section of the drop), εri,liquid, Vi,liquid 
and εri,filler, Vi,filler are the relative permittivity and voltage drop for the liquid and filler fluid portions 
of the electrode, respectively, and di is the thickness of layer i (corresponds to the dielectric, 
hydrophobic, liquid or filler layers). Differentiating the energy calculated in Equation 2.3 with 
respect to x yields the driving force as a function of frequency: 
 


















The key advantage of the electromechanical model is that it takes into account the frequency of 
the applied voltage on droplets across each layer and portion of the device – it represents the stored 
energy that results in an applied force.  
 From this, we can calculate a critical frequency (fc) for each device geometry and the 
liquids being operated.43 Below the critical frequency, we can apply the equations relative to the 
EWOD model. The force that is driving the droplet at low frequencies comes from charges 
accumulation near the three-phase contact line, which are being pulled toward the actuated 
electrode electrostatically.  The magnitude of this force depends on the capacitive energy stored 
within the dielectric. When we apply frequencies above fc, an electric field gradient is generated 
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across the droplet, generating a liquid-dielectrophoretic force to pull the droplet toward the 
activated electrode. Here, the magnitude depends on the difference in permittivity between the 
liquid and filler medium (air, in our case). In DMF, droplets are manipulated by AC frequencies 
in the order of kHz and the majority of the voltage drops across the dielectric. When inserting this 
range of frequencies in Equation 2.4, we obtain an estimation of DMF forces with magnitudes in 
the range of N, which can be applied to a wide range of fluids using driving voltages of 100-
300VRMS.  
 The driving electrostatic forces acting on the drop compete with counteracting forces. The 
first is the shear force between the droplet and the plates,44, 45 which is highly dependent on local 
surface smoothness and heterogeneity, dictated by the quality of dielectric and hydrophobic 
coating and resulting nano- and micro- scale roughness of the hydrophobic surface. The second 
factor impeding droplet movement is the viscous drag force resulting from displacement of the 
filler fluid during droplet translation.45 As soon as the driving force is greater than both the shear 
and viscous drag forces, droplet movement can be observed. Overcoming such movement 
limitations is critical in enhancing droplet movement, and the optimization lies in surface 
characterization, use of surfactants, device design and the device hydrophobicity. 
 We must note that for most DMF systems, the forces calculated by electrowetting and 
electromechanical models reach consensus. In this thesis, we are manipulating conductive liquids 
(media charged with salts) in air, which makes the energy stored in the filler portion of the 
electromechanical model negligible in comparison to that in the liquid portion (𝜀𝑟𝑖,𝑙𝑖𝑞𝑢𝑖𝑑 ≫
𝜀𝑟𝑖,𝑓𝑖𝑙𝑙𝑒𝑟). In addition, the energy that is stored in the liquid layers are negligible in comparison to 




Figure 2.1 – Single-plate and two-plate configurations for DMF.  
(Image obtained from Choi et al.46) 
 
 
2.2 Digital Microfluidics and Automation 
The greatest advantage of digital microfluidics is perhabs its amenability to integrating 
automation systems47, 48 and coupling the platform to external detectors (or internal in-line 
detectors49, 50) for real-time or downstream biological analysis. 51, 52 The core of DMF automation 
systems interfaces with a DMF device which enables droplet movement with a standard set of 
basic instructions written by the user. The user will interact with the graphical user interface (GUI) 
to program a set of instructions to dispense, move and split droplets, merge droplets together and 
to mix resulting samples and sort droplets for analysis (Figure 2.2). Such automation gives DMF 





Figure 2.2 – Operations performed on a DMF device.  
(Image obtained from Choi et al.46) 
 
Typically, DMF automation systems rely on an array of relay switches, each of which is 
responsible for one individual electrode on the device and relays AC or DC voltages to it when 
instructed. The state of the switches is controlled through a computer and microcontroller. 
Specifically, our automation system (Figure 2.3) consists of a MATLAB program (Figure 2.4) that 
is used to control an Arduino Uno microcontroller. Driving input potentials of 130-270 VRMS are 
generated by amplification of a sine wave output from a function generator operating at 10 kHz by 
an amplifier and delivered to the PCB control board. The Arduino controls the state of high-voltage 
relays that are soldered onto the PCB control board.  The logic state of an individual solid-state 
switch is controlled through an I2C communication protocol by an I/O expander. This control board 
is mated to a pogo pin interface (104 pins), where each switch delivers a high-voltage potential (or 
ground) signal to a contact pad on the DMF device. See our GitHub registry 
(https://github.com/shihmicrolab/Automation) to assemble the hardware and to install the open-
source software program to execute the automation system. 
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The ideal result of the DMF automation system is that every set of instructions would 
equate to a droplet movement (e.g., mix, dispense, split) towards the energized electrode.  
However, due to surface heterogeneity or roughness or the contents of the droplet, every 
application of a potential does not easily translate to a movement on the device.  This behaviour is 
exacerbated when the droplet constituents contains cells or proteins as they tend to ‘biofoul’ the 
surface and render the device useless over a few actuations.53, 54  Appendix A describes our 
published work in trying to alleviate this issue, through use of an image-based feedback system to 
monitor droplet movement in real-time and overcome droplet failure by providing additional 
driving voltages until the droplet completes the desired operation.55  
 





Figure 2.4 – Graphical User Interface.  
 
 
2.3 Digital Microfluidics and Cell Culture 
Numerous cell-based applications have been explored on microfluidic platforms, with the 
majority of these studies being conducted in microchannels. Microchannels are very useful in 
establishing well defined chemical gradients due to the laminar flow of the system.56 Droplets-in-
channel have also been widely used for cell-based assays, whereby the encapsulation of 103 to 106 
single cells in isolated droplet microbioreactors has been popularized for high-throughput 
genomics, transcriptomics and single-cell sequencing.10, 57, 58 Finally, digital microfluidics has 
been rapidly developing cell-based applications, popularized by its ability to rapidly reconfigure 
fluid handling on-demand to manipulate cells and reagents in a highly controlled manner.59-61    
In recent years, DMF has been shown to be amenable for two-dimensional cell culture, 
showing great promise for miniaturizing cell culture and assays. DMF has been growing in 
popularity for cell-based applications because it enables precise manipulation of droplets of 
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different reagents with different volumes, the possibility to rapidly reconfigure fluidic paths using 
a software-friendly automation system, handle cells with very low shear stress and the possibility 
of integration with other external equipment for real-time monitoring and downstream analysis. 
Compatibility for the culture of suspension cells in liquid media was initially shown in 2008 with 
Jurkat T-cells, with droplets containing cells being manipulated on a hydrophobic surface resistant 
to adhesion – validation was performed by assessing cell viability, which was shown to be 
comparable to macroscale (96-well plate) cell culture.60 Such miniaturization resulted in 100-fold 
reductions in reagent volumes. The two-plate format of DMF proves microvessel 
compartmentalization, where droplet mixing by translation allows for cell growth, and droplet 
splitting and merging enables dilutions and cell passaging.  
DMF was initially problematic for adherent cell culture given the hydrophobic nature of 
the surfaces, being incompatible with cell adhesion. Preliminary studies on surface 
functionalization were performed using dried extracellular matrix protein spots to overcome the 
hydrophibicity of DMF devices.60 In this system, adherent mammalian cells were successfully 
grown, subcultured and transfected. However, the reproducibility of such culture protein spots was 
low, which posed a problem for replicating experiments. To overcome this challenge, a 
microfabrication procedure was developed to create hydrophilic spots on the hydrophobic top-
plate by a fluorocarbon lift-off technique.62 This technique has also been demonstrated for culture 
of immortalized cell lines and was particularly successful at culturing more sensitive cell types (ie: 
primary cells). Top-plate surface functionalization enabled separate functions for both plates, with 
the continuous electrode-bearing top-plate responsible for adherent cell culture and the patterned 
electrode-bearing bottom-plate responsible for fluid handling (Figure 2.5). Such a development 
led to the discovery of a new fluidic phenomenon, coined “passive dispensing”, which refers to 
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the pinning of a portion of a droplet to the hydrophilic site when a bigger droplet is translated 
across that site (Figure 2.5).63 The formed sub-droplet acts as an individual microwell, in which 
cell-based experiments can occur. Passive dispensing enabled precise cell seeding and subsequent 




Figure 2.5 – DMF Cell Culture Strategy.    
(a) Two-plate DMF design with cell culture sites on the top plate. (b) Side-view schematic showing 
adherent cells culture on the top-plate. (c) Microscopy image of a confluent microwell. (d) Frames 
from a video depicting the process of passive dispensing, producing a microwell.    
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Chapter 3. Gene Editing and Thesis Objectives 
 
We hereby review the biological stakes that we will be addressing with our platform, 
presenting gene editing techniques with a special focus on CRISPR-Cas9 in the context of cancer 
research, and comment on the technological limitations in operating CRISPR-Cas9 today. This 
commentary will lead to the presentation of my thesis objectives. 
 
3.1 Introduction to Gene Editing Techniques 
Systematic loss-of-function screens and precise tweaking of the human genome is 
attracting an immense attention for the functional characterization of elements inherent in genetic 
pathways, the identification of components of cellular signaling pathways and the repair of 
mutated genes.64 The Online Mendelian Inheritance of Man database (OMIM, 
http://www.omim.org/) serves as an online catalog of human genes and genetic disorders and 
shows that out of the approximately 20,000 annotated genes, 3,890 genes have already been paired 
with disease phenotypes. With the rapid drop in sequencing costs, the collaborative efforts around 
gene annotation projects (i.e.: the human genome project) and the development in sequencing 
methods from genomes of diseased individuals, there has been an exponential growth in the 
knowledge of the biological functions encoded in the genome and on the genetic basis of inherited 
diseases and cancer.65, 66 Such a genomic revolution has poised researchers to rapidly develop new 
methods to determine the influence that genotype has on phenotype, thus providing great promise 
for genomics in medicine. Thus far, the most common gene therapeutic strategies are viral gene 
therapy, where original gene function is restored through retrovirus action,67 and RNA interference 
that target the pools of cytoplasmic mRNAs for repression of defective genes by directed knock-
21 
 
down of the transcript.68 Both of these strategies are limited in many respects, such as 
dysregulation at the transgene integration site with gene therapy or only partial, transient and 
unprecise repression of gene expression by RNAi.69, 70 Such limitations have stressed the 
development of new technologies to precisely regulate gene expression at the genome level. 
Introducing genomic sequence changes in a targeted manner into living cells is also a 
potential avenue for therapy of genetic diseases.71 Novel gene editing technologies are thus critical 
to increase the proficiency of such screens and therapies. Therapeutic genome editing in diseased 
cells and tissues to remove or correct deleterious mutations are being actively explored since the 
development of genome editing technologies based on programmable nucleases,66 notably zinc 
finger nucleases (ZFNs),72 transcription activator-like nucleases (TALENs)73 and clustered 
regularly interspaced short palindromic repeat (CRISPR)-associated nuclease Cas9.74 These three 
technologies are characterized by a DNA-binding motif and a DNA-cleavage module, and generate 
double-strand breaks (DSBs) at the target loci, stimulating cellular DNA repair mechanisms 
including error-prone non-homologous end joining (NHEJ) or homology-directed repair (HDR). 
75, 76 Both these mechanisms result in genomic disruption, deletion, correction or addition at the 




3.2 Special Focus on CRISPR-Cas9 
First discovered in prokaryotes, the type II CRISPR-Cas9 adaptive immune system was 
shown to facilitate RNA-guided site-specific DNA cleavage of foreign genetic elements, including 
plasmids or phage-injected viral RNA.77 Similar to the adaptive immune system in humans which 
relies on memory T cells for rapid elimination of any returning foreign antigens, bacteria have a 
similar mechanism to cope with returning foreign nucleic acids. Initial studies performed in S. 
thermophiles identified Cas9 as a key player for defense against viral invasion, by cutting the 
foreign plasmid or phage. Further studies revealed a genomic CRISPR locus, with upstream 
transactivating CRISPR RNA (tracrRNA), the cas operon with genes encoding various cas proteins 
and the CRISPR repeat-spacer array, consisting of the crRNA. Such bacterial systems utilize an 
RNA duplex, tracrRNA:crRNA, that base pairs with the viral or plasmid foreign species and 
recruits the Cas9 endonuclease to generate a site-directed double stranded break.78 In further 
research, the dual RNA was engineered as a single guide chimera RNA (sgRNA) with a seed 
sequence at the 5’ end and the dCas-handle structure at the 3’ end to bind Cas9.79 Next, the 
discovery of inherent repair machinery to mediate the repair of DSBs that would otherwise be 
lethal led to an unprecedented strategy for targeted genetic engineering.80 The advent of such a 
technology enables the systematic interrogation of gene function in mammalian cells, study of 
genomic rearrangements and the progression of cancer and other diseases and shows great promise 
in gene therapy and personalized medicine.78, 81, 82  
Since its discovery, the CRISPR-Cas nuclease system has been used in numerous 
organisms including mouse and human cell lines.77, 83, 84 The popularity of this system can be 
attributed to its specificity, efficiency, ease of reprogramming and given that it is well suited for 
high-throughput and multiplexed gene editing.85, 86 In the two component CRISPR-Cas9 system, 
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an sgRNA directs the Cas9 nuclease to a specific DNA target region where the nuclease gets 
activated and acts as a pair of genetic scissors to introduce a double-strand break.87 Designed 
sgRNAs directs and targets Cas9 to a 20-22 bp DNA target region using Watson-Crick base 
pairing. The system we are utilizing, CRISPR-Cas9, has a prerequisite for its target DNA – it must 
immediately precede a 5’-NGG protospacer-adjacent motif (PAM) sequence which is essential for 
Cas9 activation. Two cellular mechanisms follow to address the double-strand break and attempt 
repair (Figure 3.1). In the first scenario, NHEJ leaves scars in the form of insertions/deletions 
(indels), which enables loss-of-function mutations into the genome at specific target genomic 
loci.85, 88 NHEJ is harnessed to mediate gene knockouts, given that indels inserted within exons 
can produce frameshift mutations and premature stop codons, thereby inhibiting protein expression 
at the gene level.89 Furthermore, an exogenous donor DNA can be added to the system to leverage 
homology directed repair (HDR) for precise, defined genetic modifications at your target region. 
 
 
Figure 3.1 – Endogenous DNA dsBreak repair mechanisms promoting gene editing.    




3.3 CRISPR-Cas9 in Cancer Research 
Recent efforts in cancer characterization are shifting towards a more personalized approach rather 
than hierarchical classifications based on chemosensitivity experiments.90 Cancer is a 
heterogeneous disease that highly differs in genetic makeup and relies on different pathways for 
survival – this gives rise to a wide-range of potential responses to different anti-cancer agents.91, 
92  One method that has been rapidly growing in interest is to use CRISPR-based screens to 
systematically identify the genes that are required for the survival and proliferation of mammalian 
cells.85, 91-97 Such a method enables complete and permanent inactivation of genes and can offer 
insight into the genetic basis of the disease and lead to the identification of new drug targets.94, 98-
101 Several groups have reported successful editing of endogenous genes in cells in culture via 
transfection of plasmid DNA102 or stable delivery into cells through the use of lentiviruses or other 
retroviruses103.  The advantages of the CRISPR-Cas9 system have generated immense interest in 
using this approach for screens aimed at identifying potential drug targets for cancer treatment.94, 
98-105   
The most common format for these loss-of-function perturbations is in vitro ‘pooled’ 
screens94, 99, 103 relying on the delivery of Cas9 nucleases and a ‘pool’ of guide RNAs (sgRNAs) 
into the cells by transfection or transduction.  Pooled libraries enable screens that simultaneously 
assess the effect of knocking out hundreds to thousands of individual genes at multiple loci in a 
phenotypic readout, such as proliferation or metastasis assays.  Although such developments 
provide new opportunities for drug target identification and validation, interpretation of results in 
a pooled format rely on differential representation of guide RNAs after vs before (as assessed by 
Next-Generation Sequencing) and rely on enrichment of multiple guide RNAs as a validation of 
target relevance.99, 104 Furthermore, the complexity of population dynamics, each cell being in 
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competition with many others, may contribute to biases resulting in higher relative abundance of 
some perturbations compared to some others.  An alternative to ‘pooled’ screens is to implement 
‘arrayed’ screens where cells are genetically perturbed only with one known gene target.106, 107  
This can potentially enable use of a wider range of cellular phenotypes to be investigated.108-110 
Limitations of arrayed experiments are the associated costs (usually an order of magnitude more 
expensive than pooled libraries111) since they require special facilities that use automation for the 
handling of plates and the inefficient workflow that includes labor-intensive preparatory work to 
build and produce individual guide libraries and transferring the samples to other platforms for 
analysis.  Thus, an automated and integrated platform that will culture cells for days, enable 
efficient handling of mammalian cells and reagents, express the gene editing machinery targeting 
an individual gene or locus in cells, and assay cell phenotypes will be beneficial for these arrayed-
type experiments to save overall costs and to improve the workflow that minimizes the time frame 





3.4 Technological Challenges in CRISPR-Cas9 Operation 
Arrayed libraries are typically generated in multi-well plates, where each well contains a 
virus or vector, or reagents with a guide targeting a specific gene.  The tools used for these types 
of experiments, such as automated robotics coupled with flow cytometry, can provide an 
exploration of complex phenotypes arising from single perturbations.  Despite their outstanding 
features in reducing cell death or limiting off-target mutagenesis associated with editing,112, 113 
these techniques suffer from three key limitations.  First, available liquid handling technologies, 
data acquisition equipment and data storage/processing systems have traditionally been expensive 
and have large footprints that are well outside of the budgetary reach of many laboratories.  In 
addition, the programming software packages are not standardized between laboratories which 
frequently discourages inter-disciplinary scientists and researchers to use robots as it usually 
requires more time and effort to instruct a robot to perform a task.  Second, liquid handlers for cell 
culture and sample preparation have multiple sources of variability (especially at the nL volumes) 
which can cause unintended perturbations related to the gene-editing process – e.g., different 
volumes can alter cell growth resulting in unequal number of cells across wells of a plate.  This 
can pose variability issues with downstream analysis in terms of measuring transfection and 
knockout efficiencies related to cell density.  Third, there is a lack of standardization in assay and 
in instrument set-up for flow cytometry and especially how flow data are analyzed and reported.  
Thus, these approaches may present additional challenges to the already complex procedures of 
gene editing. 
 With such high demand for gene editing and the incredible number of genes to be screened 
to fully characterize diseases, technology must be at the cutting-edge. A strategy to alleviate the 
challenges described above is to use flow-based microfluidics and fluorescent microscopy 
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techniques114-116.  The development and maturation of these microdevices and optical techniques 
have been a boon to be used for cell-based assays and genomics.117-123  Microfluidics allows the 
manipulation of small volumes of liquids in nanoliter (or smaller) scales in interconnected micron-
sized dimension channels and enables the automated delivery of chemical stimulant to cells. The 
resulting cellular responses can be imaged with fluorescent reporters or fluorescent labelling 
techniques.  For gene-editing assays, this includes delivery of Cas9 into the cells and visualizing 
them via a fluorescence reporter or using Western blot techniques to determine if the Cas9 has 
been delivered into the cell.124, 125 These methods offer an exciting new framework into gene-
editing, but do not incorporate two key steps in the gene-editing process.  First, the serial nature 
of flow-based microfluidics present challenges in delivering many reagents (i.e. lipids, DNA, 
culture medium, drugs, etc…) needed for the gene-editing process.  Indeed, valves can be 
integrated into the PDMS-based microdevice, but this can be very complicated to setup (in terms 
of alignment and insertion of tubing) and to operate.126, 127 Second, two key steps in gene editing - 
cell culturing and analysis have been performed off-chip – i.e. the cells have been cultured in flasks 
analyzed by flow cytometry.  A standardized automated gene-editing platform that can automate 




3.5 Thesis Objectives 
To address the challenges described above, we report here a new droplet-based method for 
gene editing called microfluidic Automated CRISPR-Cas9 Editing (ACE) which can automate all 
the steps for gene-editing – culture, delivery, and analysis.  In this work, we report the application 
of ACE to evaluate the well-characterized mitogen-activated protein kinase or extracellular signal-
regulated kinase (MAPK/ERK) pathway128, 129 downstream editing of the Raf-1 gene with and 
without a Raf-1 inhibitor Sorafenib Tosylate.  The results recapitulate what is known about the 
pathway and its effect on cell viability, but the technique presented here shows that we are capable 
of conducting an automated gene-editing workflow from cell culturing to analysis with an open-
source automation system coupled with a standardized pipeline to analyse the transfected/knockout 
fluorescent cells.  These results (to our knowledge) are the first of their kind and serve as examples 
of what is possible for the future – a new technique for probing other types of cancer and serve as 
a platform for ex vivo applications relating to personalized medicine that require automated cell 
culture, transfection, CRISPR-Cas9 editing, and drug inhibition.   
My research was segmented into four steps, described below in chronological order: 
1. Chip design: The device layout was established for cell culture and optimized for 
delivery of CRISPR-Cas9 components to cells. 
2. Platform validation: Transfection conditions were optimized using a dummy 
fluorescent reporter vector on-chip to obtain efficiencies similar to those in the multi-
well plate format. 
3. Proof-of-Concept: All-in-one pCRISPR vectors targeting a stably integrated 
fluorescent gene were used and knock-out efficiency on- and off-chip using a 
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phenotypic fluorescent readout were compared to establish the platform as an efficient 
gene editing micromachine. 
4. Application: To confirm the broad applicability of our platform, we performed a 
proliferation assay coupling both CRISPR editing with drug inhibition to validate our 
innovation’s potential in cancer research. 
These results (to our knowledge) are the first of their kind and serve as examples of what 
is possible for the future – a new technique for probing other types cancer and serve as a platform 




Chapter 4. Methodology: Operating Biology On-Chip 
 
In this chapter, I will describe my methodology for integrating the biological processes 
relevant to CRISPR-Cas9 gene editing on the ACE platform. Topics covered in this section are 
CRISPR plasmid assembly techniques, macro-scale cell experiments. I will also describe device 
fabrication, assembly, and operation with the automation system before reviewing methods for 
microfluidic cell culture, transfection and knock-out. Finally, I will present the data analysis 
methods, namely image processing and protein expression experiments.  
 
4.1 Reagents and Materials 
Microfluidic device fabrication reagents and supplies included chromium-coated glass slides with 
S1811 photoresist from Telic (Valencia, CA), indium tin oxide (ITO)- coated glass slides, RS =15-
25 (Cat no. CG-61IN- S207, Delta Technologies, Loveland CO), FluoroPel PFC1601V from 
Cytonix LLC (Beltsville, MD), MF-321 positive photoresist developer from Rohm and Haas 
(Marlborough, MA), CR-4 chromium etchant from OM Group (Cleveland, OH), AZ-300T 
photoresist stripper from AZ Electronic Materials (Somerville, NJ), DuPont AF from DuPont 
Fluoroproducts (Wilmington, DE). Transparency masks for device fabrication were printed from 
CADArt (Bandon, OR) and polylactic acid (PLA) material for 3D printing were purchased from 
3Dshop (Mississauga, ON, Canada). General chemicals for tissue culture were purchased from 
Wisent Bio Products (Saint-Bruno, QC, Canada). Invitrogen Lipofectamine 3000 Transfection 
Reagent was purchased from Thermo Fisher Scientific (Waltham, MA). Unless specified 
otherwise, general-use chemicals and kits were purchased from Sigma-Aldrich (St. Louis, MO). 
Plasmids for this study were purchased from Addgene or donated (see Table 4.1) and primers were 
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purchased from Invitrogen (Waltham, MA), and genes (438 bp) were synthesized by IDT 
(Coralville, IA)  (Table 4.2). Sorafenib Tosylate was purchased from Selleckchem (Houston, TX). 
 
Table 4.1 – Cells and Plasmids used in this study 
Cells Genotype Source 
E. coli DH5α 
fhuA2 Δ(argF-lacZ)U169 phoA 
glnV44 Φ80 Δ(lacZ)M15 gyrA96 
recA1 relA1 endA1 thi-1 hsdR17 
V. Martin 
Cell Line Transgene Integration Source 
NCI-H1299 (Human lung squamous cell 




Plasmids Relevant characteristics Addgene # 
mCherry2-N1 KanR 54517 
All_in_one_CRISPR/Cas9_LacZ AmpR 74293 
pSpCas9(BB)-2A-Puro (PX459) v2.0 AmpR, PuroR 62988 
 
Table 4.2 – CRISPR Target Sequences 
Custom pCRISPR 
Plasmids 
Custom Sequence PAM Source 
pCRISPR_eGFP_191 – / ACTGCACGCCGTAGGTCAGGG TGG This study 
pCRISPR_eGFP_314 + / GCAACTACAAGACCCGCGCCG AGG This study 
pCRISPR_eGFP_369 + / TCGATGCCCTTCAGCTCGATG CGG This study 
pCRISPR_eGFP_497 + / TCAAGATCCGCCACAACATCG AGG This study 
pCRISPR_eGFP_683 – / CCATGCCGAGAGTGATCCCGG CGG This study 
pCRISPR_RAF1_94 + / GCCGCCCGAGAGTCTTAATCG CGG This study 
PX459_eGFP_12-31 + / GGGCGAGGAGCTGTTCACCG GGG Genscript 
 
4.2 Plasmid Construction and Purification 
CRISPR guide RNAs (gRNA) were synthesized (Figure 4.1) by IDT Technologies after being 
designed via the Benchling online platform (https://benchling.com/), and were PCR amplified to 
create g-blocks flanked with Esp3I type IIS restriction sites (see Table 4.3 for primers) Individual 
PCR reactions consisted of 10 L 5X Phusion buffer, 1 L dimethylsulfoxide (DMSO), 20 ng 
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template DNA, individual dNTPs and primers to a final concentration of 200 M and 0.5 M each, 
0.5 L Phusion polymerase and distilled water up to 50 L. The following PCR thermocycling 
conditions were used: initial denaturation at 98 °C for 30 s followed by 35 cycles of denaturation 
at 98 °C for 10 s, annealing at 55 °C for 30 s and extension at 72 °C for 30 s/kb, and a final 
extension step at 72 °C for 10 min.  PCR products were loaded into a 0.8% agarose gel in TAE 
buffer and resolved at 130 V for 30 min.  The corresponding bands from a gel (Figure 4.2) were 
extracted using a gel extraction kit from BioBasic (Markham, ON, Canada). The one-step gRNA 
cloning method was adapted from the Findlay et al. protocol.130 The gRNAs were assembled via 
restriction digestion/ligation into the All_in_one_CRISPR/Cas9_LacZ  backbone containing 
Esp3I cut sites on both the 3’ and 5’ ends of LacZ gene fragment.  Individual reactions consisted 
of 25 ng of the g-Block (10 ng/L), 75 ng All_in_one_CRISPR/Cas9_LacZ1 L BsmBI (10 
U/L), 1 L T4 ligase (Thermo Fisher, Waltham, MA), 2uL T4 buffer and nuclease-free water to 
20 L total. The mixture was incubated in a thermal cycler at 37 °C for 5 min, 16 °C for 10 min, 
37 °C for 15min and 80 °C for 5 min. Assembled products were heat-shock transformed into the 
LacZ deficient DH5 E. Coli strain. The transformed products were grown on LB/S-Gal agar 
blend and assembled products were discriminated by a color bias for colonies – blue colonies 
contained the LacZ fragment required for S-Gal hydrolysis, whereas white colonies possessed 
the g-block insert (i.e. without the LacZ gene). White colonies were picked and grown overnight 
before being DNA purified and sent out for sequencing by Eurofins Genomics (Toronto, ON, 





sgRNA 438 bp 








Figure 4.1 – The sgRNA sequence represents the template designed for all sgRNAs. 
It consists of the U6 Promoter, the variable seed sequence, the dCas9 handle and the S. pyogenes 
terminator. The seed sequences varied according to the target region (see Table 4.2).  All eight 
constructs were synthesized by Integrated DNA Technologies, Inc. (Coralville, IA).  
 
Figure 4.2 – PCR products of the synthesized CRISPR guides, yielding g-blocks.  
PCR products were loaded into a 0.8% agarose gel in TAE buffer and resolved at 130 V for 30 
min. These represent the g-blocks flanked with BsmBI cut sites, ready for insertion into a pCRISPR 
backbone. (1) KRAS_5608; (2) KRAS_41162; (3) RAF1_94; (4) RAF1_253; (5) RAF1_64486; (6) 
EGFP_191; (7) EGFP_314; (8) EGFP_369; (9) EGFP_497; (10) EGFP_683. 
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Table 4.3 – Primer sequences 
Gene Orientation Sequence 




SP6 sequencing primers Forward ATTTAGGTGACACTATAG 
 
 
Figure 4.3 – Blue-White Screening for pCRISPR All-in-one assembly.  
A schematic showing the procedure of inserting a CRISPR guide into a Cas9 vector backbone. An 
all-in-one pCRISPR template tailored to blue-white screening was used. The LacZα open reading 
frame, necessary to complement Δ(lacZ)M15 for functional beta-galactosidase expression, was 
inserted between two BsmBI flanking sites. One-pot assembly reactions containing the all-in-one 
pCRISPR template, the restriction enzymes, the g-block and the T4 DNA ligase were placed in a 
thermal cycler and the product was transformed into E. coli. Cells were plated on LB Agar with 
S-Gal, a colorless substrate that gets hydrolyzed by beta-galactosidase and results in blue 
bacterial colonies. Cells that were transformed with recombinant vectors of interest would be 





4.3 Macro-Scale Cell Culture, Transfection and Knock-Out 
Human lung squamous cell carcinoma dual-labeled stable NCI-H1299 cell line was purchased 
from Genecopoeia, Inc (SL001, Rockville, MD).  H1299 cells were grown in RPMI 1640 
containing 10 % fetal bovine serum with no antibiotics in a humidified chamber at 37 °C with 5% 
CO2.    
 For macroscale transfection experiments, cells were seeded (1.0 x 105 cells/mL) a day 
before transfection (day 0) to reach 70-80% confluency in 24 well-plates.  On day 1, 500 ng/L of 
DNA were pre-mixed with 1 L of P3000 reagent in 25 L of Opti-MEM and added to 1.5 L 
Lipofectamine 3000 that was pre-mixed in 25 L Opti-MEM. Lipids were then incubated with the 
DNA at room temperature for 10 min to for lipid-DNA complexes.  The complexes were pipetted 
into each individual well containing the adhered cells. On day 2, after incubation, the lipid complex 
with DNA was removed by aspiration and fresh complete media was replenished into the wells.  
Cells were stained with Hoechst 33342 and incubated for 30 min on day 3.  The cells were imaged 
with a 20x objective on an Olympus IX73 inverted microscope  (Olympus Canada, Mississauga, 
ON, Canada) that has fluorescence imaging capabilities (Hoechst: ex = 350 nm and em = 461 nm; 
GFP: ex = 488 nm and em = 509 nm; mCherry: ex = 585 nm and em = 608 nm). Fluorescence 
images were further analyzed using the CellProfiler transfection pipeline.  
 For knockout experiments, the cell seeding followed the steps described in the transfection 
experiments.  For transfection (day 1), 600 ng/L of assembled pCRISPR plasmid (with the 
inserted sgRNA) were mixed with the same reagent compositions as above (1:10 ratio of lipid 
complexes to media in wells). After cells were maintained (i.e. replaced with fresh media) on day 
3, cells were sub-cultured at a 1:4 ratio in a new 24-well plate on day 4 by washing the cells with 
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200 L of PBS and removing the cells with 150 L of 0.25 % trypsin-EDTA.  Following further 
maintenance on day 5, on day 6 the cells were stained with 1 M Hoechst 33342 and imaged using 
the same microscope (and filters) for knockout analysis using the CellProfiler knockout pipeline.  
Data were considered statistically significant at P < 0.05 using a student’s t-test. 
 
4.4 Device Fabrication and Assembly 
Digital microfluidic devices were fabricated following methods described previously.131, 132  
Briefly, designs were drawn using AutoCAD 2015 (Autodesk, San Rafael, CA) and photomasks 
were then printed in high-resolution (20,000 dpi) by CAD/Art Services Inc (Bandon, OR). The 
bottom-plates bearing patterned electrodes were formed by standard photolithography techniques, 
in the Concordia Silicon Microfabrication Lab (ConSIM). Chromium substrates coated with 
photoresist were UV-exposed through the photomask (7 s, 42.4 mW/cm2) to imprint the 
transparency mask designs. Substrates were then developed in MF-321 positive photoresist 
developer (2 min, shaking), rinsed with DI water, dried under a stream of nitrogen and baked for 
1 min at 115 °C. The exposed chromium was then etched using CR-4 chromium etchant (3 min) 
and substrates were then rinsed with DI water and dried under a stream of nitrogen. Finally, devices 
were immersed in AZ300T photoresist stripper (3 min) to remove any remaining photoresist before 
being rinsed and dried under a stream of nitrogen.  Once the patterning step was completed, the 
substrates were immersed in a silane solution consisting of deionized water, isopropanol and 3-
(Trimethoxysilyl)propyl-methacrylate (50:50:1) for dielectric priming during 15 min.  Substrates 
were rinsed with isopropanol, DI water and then dried under a stream of nitrogen. Prior to the 
addition of the polymer coatings to complete the process, thermal tape was added on top of the 
contact pads to facilitate later removal of the polymer coatings from the contact pads and allow 
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electrical contact for droplet actuation. Parylene-C was used as a dielectric which was deposited 
by chemical vapor deposition in a SCS Labcoter 2 PDS 2010 (Specialty Coating Systems, 
Indianapolis, IN) achieving a homogenous final thickness of 7 m. FluoroPel PFC1601V was used 
as a hydrophobic coating and was spin-coated in a Laurell spin-coater at 1500 rpm for 30 s 
followed by post-baking on a hot-plate (180 °C, 10 min).  
 The DMF top-plates consist of a continuous ground electrode formed from an indium tin 
oxide (ITO) coated glass substrate. For typical ground plates, ITOs were spin-coated with the 
FluoroPel PFC1601V using the same program as described in the bottom-plate fabrication 
procedure.  ITOs bearing an array of hydrophilic spots (i.e., circular regions of exposed ITO) for 
on-chip tissue culture were microfabricated using a fluorocarbon-liftoff procedure (following 
procedures described previously.61, 133  ITOs were cleaned by immersion in an RCA solution 
comprising of DI water, 28% aqueous ammonium hydroxide, 30% hydrogen peroxide (5:1:1 v/v/v) 
for 30 min at 80 °C on a hotplate. After rinsing, drying and dehydrating (2 min at 95°C), the 
substrates were spin-coated with Shipley S1811 photoresist (10 s, 500 rpm, ACL=100 rpm and 60 
s, 3000 rpm, ACL=500 rpm) and baked at 95 °C for 2 min. Slides were cut to the desired size (i.e.: 
50 x 75 mm) using a Cuter’s Mate (Creator’s Stained Glass, Victoria, BC) and vented under a 
stream of nitrogen. Substrates were exposed through the photomask with an array of six 1.75 mm 
diameter circular features (10 s, 42.4 mW/cm2) and developed in MF-321 (3 min). After rinsing, 
air-drying and dehydrating (1 min, 95°C), top-plates were then flood exposed (10 sec, 42.4 
mW/cm2), spin-coated with 1% Teflon in FC-40 (10 s, 500 rpm, ACL = 100 rpm and 60 s, 3000 
rpm, ACL = 500), and post-baked on a hotplate (165 °C, 10 min). After allowing to cool on 
aluminum foil for 2 min, substrates were immersed in acetone with gentle agitation for 10-15 s 
until the Teflon-AF over the patterned sites was lifted off.  After being rinsed with DI water and 
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dried under a stream of nitrogen, droplets of AZ300T stripper was gently placed over the spots and 
substrates were placed aside for 1 min followed by rinsing with DI water and air-drying. Post-
baking followed to reflow the Teflon-AF at 165°C, 210°C and 300°C for 5 min at each 
temperature. See Figure 4.4 for complete device fabrication schematic. 
 Complete devices were assembled with the continuous ground ITO top-plate and the 
chromium electrode-bearing bottom plate, being joined by stacking two layers of double sided tape 
to a gap height of approximately 140 m.  Alignment of the ITO top plate above the bottom plate 
was performed with care such that the edge of the top plate was adjacent to the outer-edges of the 
reservoir electrodes of the bottom-plate pattern (see Figure 5.1). Moreover, each 25 mm x 75 mm 




Figure 4.4 – DMF Device Fabrication.  




4.5 Automation Setup and Device Operation 
The automation system (Figure 4.5) consists of a MATLAB (Natlick, MA) program that is used 
to control an Arduino Uno microcontroller (Adafruit, New York, USA). Driving input potentials 
of 130-270 VRMS were generated by amplification of a sine wave output from a function generator 
(Agilent Technologies, Santa Clara, CA) operating at 10 kHz by a PZD-700A amplifier, (Trek 
Inc., Lockport, NY) and delivered to the PCB control board. The Arduino controls the state of 
high-voltage relays (AQW216 Panasonic, Digikey, Winnipeg, MB) that are soldered onto the PCB 
control board.  The logic state of an individual solid-state switch is controlled through an I2C 
communication protocol by an I/O expander (Maxim 7300, Digikey, Winnipeg, MB).  This control 
board is mated to a pogo pin interface (104 pins), where each switch delivers a high-voltage 
potential (or ground) signal to a contact pad on the DMF device. See our GitHub registry 
(https://github.com/shihmicrolab/Automation) to assemble the hardware and to install the open-
source software program to execute the automation system. 
 To start gene-editing experiments, reagent loading was achieved by pipetting a droplet of 
liquid onto the outer-edge of a reservoir electrode and adjacent to the gap between the bottom and 
top plates and actuating the reservoir electrode.  Once inside the reservoirs, the droplets were then 
actively dispensed, moved, mixed or merged by sequential actuation of neighboring electrodes on 
the bottom plates.  Active dispensing was achieved over three electrodes and results in a droplet 
with a diameter of the same size as the electrodes (i.e. a unit droplet). To initiate passive 
dispensing, it is achieved by moving an actively dispensed droplet over the vacant lift-off spot.  At 
times, contents on this spot may be displaced with the contents of a new source droplet.  Generally, 
all droplets containing proteins were supplemented with 0.05% Pluronics F-68.  Waste and unused 
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fluids were removed by delivering them to reservoirs and removed using KimWipes (Kimberly-
Clark, Irving, TX). 
 
 
Figure 4.5 – Microfluidic automation system for gene-editing.  
The automation system consists of a custom MATLAB program interfaced to an Arduino Uno 
microcontroller. The Arduino controls the state of high-voltage relays on a switching control 
board. Sine waves are generated from a function generator operating at 10kHz and amplified 
using a high-voltage amplifier, producing driving input potentials of 130-270 VRMS to the control 
board. The control of the state of an individual switch is done through an I2C communication 
protocol using an I/O expander. The control board is mated to a pogo pin board, where each 
switch is wired to an individual pogo-pin, in contact with a contact pad. The whole system is 
imaged live through a CMOS camera. 
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4.6 Microfluidic Cell Culture, Transfection and Knock-Out 
DMF was used to automate the protocols required for gene editing including cell seeding, culture, 
lipid transfection, reagent delivery, staining, washing, and drug inhibition. In all droplet 
manipulation steps, the device was oriented in standard configuration, with the top plate on top, 
while in all incubation steps, the devices were inverted, with the top plate on the bottom and in a 
3D- printed humidified chamber (Figure 4.6-a).  Before seeding cells onto DMF devices (day 0), 
cell cultures were grown in T-75 flasks and were rinsed with PBS, trypsinized and suspended in 
10 mL of complete media.  After centrifugation at 1,000 x g for 5 min, the cell pellet was suspended 
in 2 mL of complete media (and supplemented with 0.05% w/v Pluronics F-68) such that the initial 
concentration of cells is ~1.5 x 106 cells/mL.  
 To seed and culture cells (day 0), 2 L of cells at 1.75 x 106 cells/mL in culture medium 
were pipetted onto the edge of the ITO and actively dispensed from the reservoirs into 690 nL unit 
droplets.  These droplets were sequentially passively dispensed on each vacant lift-off spot forming 
285 nL droplets on the hydrophilic sites.  The excess liquid from the spot was actuated to a waste 
reservoir and removed with a KimWipe. The device was inverted and incubated in a 37 °C 
incubator with 5% CO2 overnight allowing the cells to adhere onto the hydrophilic spot.  In the 
next 7 steps, a sequence of transfection reagents was mixed to form lipid complexes and delivered 
(via passive dispensing) to each hydrophilic site that contains cells on day 1.  (1) 1 L of 
Lipofectamine was diluted in 25 L of Opti-MEM and premixed and 2 L was added to a reservoir.  
(2) 500 ng/L of the plasmid DNA to be inserted and 1 L of P3000 reagent diluted in 25 L of 
Opti-MEM was also added to another reservoir.  (3) Both reagents were actively dispensed (360 
nL each), merged and mixed in a square configuration using 2 x 2 electrodes and incubated for 10 
min to form lipid complexes. (4) The lipid complexes were diluted in a 1:1 ratio by combining 
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with a 690 nL unit droplet of Opti-MEM.  (5) After mixing, the complexes were delivered to the 
cells via passive dispensing 6 x 285 nL and incubated for 24 h overnight.  (6) The lipid complexes 
on the cells were removed by passively dispensing 6 x 285 nL of fresh complete media.  (7) After 
24 h, 6 x 285 nL of 1 M Hoechst stain in liquid media was passively dispensed to each well and 
fluorescence images were acquired to measure transfection efficiency. In transfection optimization 
experiments, lipid:media ratios in step 4 were changed by performing serial dilutions – by splitting 
the initial droplet containing the 1:1 diluted complexed DNA into two daughter droplets (360 nL 
each) and mixing it with a unit droplet of liquid media (690 nL). mCherry transfection efficiency 
was monitored on the device by microscopy, mounting the devices on a custom 3D-printed 
microscope holder (Figure 4.6-b). Fluorescence images were further analyzed using the 
CellProfiler transfection pipeline.  
 For assessing GFP knockout efficiency, 2 L of cells (~1.75 x 106 cells/mL) were pipetted 
onto the reservoir and a unit droplet was actuated to the vacant lift-off spot. After overnight 
incubation, the adhered cells were transfected with 600 ng/L of pCRISPR (with the inserted 
sgRNA) following the steps for transfection (steps 1-6).  Cells were maintained until day 5 by 
passively dispensing fresh media daily (6 x 285 nL) to each cell culture site.  GFP knock-out was 
monitored on the device by using microscopy and mounting the devices on a custom 3D-printed 
microscope holder (Figure 4.6-b) to ensure healthy cells during image acquisition.  On day 5, the 
microwells were rinsed with PBS followed by 0.25% trypsin-EDTA by passively dispensing a unit 
droplet across each well.  Following incubation at 37°C for 5 min, the top-plate was disassembled 
from the bottom-plate and 100 L of complete media was pipetted directly onto each hydrophilic 
spot and transferred to an individual well of a 96-well plate and incubated for 2 days. On day 6, 1 
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M Hoechst stain in liquid media was added to each well and fluorescence images were acquired 
to measure knock-out efficiency using the custom CellProfiler knock-out efficiency pipeline.  
 
 
Figure 4.6 – 3D-Printed Humidified Chamber and microscope holder for imaging.  
(A) Cell humidified chamber with cover to prevent evaporation of droplets. The design consists of 
a rack above a water reservoir, on which the devices are placed and of a lid to prevent evaporation 
and enable saturation in humidity. (B) Microscope holder tailored to digital microfluidic devices, 
with opaque cover for fluorescence microscopy. 
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4.7 Cell Imaging and CellProfiler Pipeline 
Top plates bearing stained and fluorescent cells were analyzed using an inverted Olympus 
microscope.  Typically, images were acquired using an Hamamatsu digital camera (Model C1140-
42U) camera with the HCImageLive software. We typically acquired images using a UV (250 ms 
exposure time), GFP (500 ms), or mCherry filter set (1000 ms). 
Images from the microscope were analysed using the open-source CellProfiler 2.2.0 
r9969F42 software package (http://www.cellprofiler.org/).134 A custom pipeline was developed, 
including image cropping, identifying individual and overlapping cells from Hoechst-stained and 
mCherry fluorescent images, counting total number of cells, measuring the size and shape of cells, 
creating binary images of the cells (i.e. black and white images), and comparing knocked-out and 
non-knocked out cells (UV and GFP channels). For transfection analysis, the pipeline is divided 
into four modules.  In module 1, the software was instructed to smooth the Hoechst-stained image 
with a Gaussian filter ( and uses the Otsu Global thresholding method to detect objects with 
diameters of 20-100 pixel units (two classes, threshold correction factor = 0.8).  Neighboring pixels 
are grouped into objects and undesired clumped objects (i.e. two close overlapping objects) are 
declumped using intensity segregation.  In module 2, the software was instructed to threshold the 
mCherry image to select cells that have the plasmid (threshold correction factor = 1) and binarize 
the image to have black (corresponding to mCherry-negative) and white (mCherry-positive) 
regions.  In module 3, the software was instructed to overlap images from module 1 and 2 where 
the image from module 2 served as a mask for the identified nuclei in module 1. All the nuclei-
stained cells (from module 1) overlapping with an mCherry-positive region (module 2) were 




Equation 4.1: Percentage of fluorescent cells 
𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (%) =  [𝑜𝑣𝑒𝑟𝑙𝑎𝑝𝑝𝑖𝑛𝑔 𝑛𝑢𝑐𝑙𝑒𝑖 𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑐𝑙𝑒𝑖⁄ ] × 100 
  
The result corresponds to the proportion of mCherry-positive nuclei (i.e. transfected cells) 
versus the total number or nuclei.  Each data point was further corrected from the negative control 
cells (i.e. non-transfected cells) using the same pipeline.    
For the knockout pipeline, four similar modules were created to analyse knockout 
efficiencies.  In module 1, the software followed the instructions for the transfection pipeline. In 
module 2, a GFP image was thresholded using the Otsu method (two classes, 0.65 threshold 
correction factor).  Module 3 consisted of overlapping the image with the image from module 2 
serving as a mask for the image from module 1.  Nuclei-stained cells that overlap with GFP-
positive cells (90% of its total pixels) were not considered as knocked-out cells.  Module 4 
followed equation 1 – total number of knocked out cells from module 3 divided by the total number 
of cells obtained from module 1 to obtain knockout efficiencies. 
 
4.8 Western Blot Experiments 
Cells were transfected with the desired pCRISPR (with sgRNA inserts) plasmids in 10 cm dishes, 
with reagents being scaled up from 24-well plates with a multiplication factor of 28.95.  Dishes 
were incubated until cells reached 90-100% confluency. Cell lysis buffer was prepared by adding 
a tablet of protease and phosphatase inhibitors to 10 mL of Pierce IP Lysis Buffer (Thermo Fisher, 
Waltham, MA).  All subsequent solutions and consumables were placed on ice to prevent protein 
degradation.  Cell media was aspirated from the dish and cells were rinsed with 5 mL of ice-cold 
PBS. Next, 750 L of ice-cold lysis buffer was added to the dish, and the Petri dishes were 
incubated on ice for 5 min, with periodic mixing. The produced lysate was transferred to a 
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microcentrifuge tube (using a cell scraper) and centrifuged at 12 300 rpm for 10 min at 4°C. The 
supernatant was transferred to a new tube and stored at -20°C.  Protein concentration determination 
was performed for each lysate using the manufacturer’s protocol for BSA Protein Concentration.  
 For the SDS-PAGE, 25 L of Laemmli Loading Buffer (Bio-Rad, Hercules, CA) was 
added to 75 L of cell lysate, and placed on a heat block at 100 °C for 10 min while the samples 
were returned to ice for 5 min. Bio-Rad pre-cast gels (Bio-Rad, Hercules, CA) were placed in the 
Bio-Rad SDS-PAGE running apparatus (Bio-Rad, Hercules, CA) and the chamber was filled with 
running buffer. Two gels were run in parallel loading different amounts of protein (20 g and 40 
g), and the running apparatus was operated at 150 V for 60 min at 4 °C. The gels were then 
removed from their cast and immersed in ice-cold transfer buffer for 10 min to equilibrate. 
Nitrocellulose membranes and blotting paper were also immersed in transfer buffer to equilibrate. 
The setup was stacked in a vertical orientation (sponge, blotting paper, gel, nitrocellulose 
membrane, blotting paper, sponge) and clamped. The clamp was placed in the transfer apparatus 
which was run at 82 mA at 4 °C.  
After overnight transfer, the membranes were removed and placed face-up in PBS for 5 
min on an agitator.  Membranes were then immersed in LiCor PBS blocking buffer (Lincoln, NE) 
for 1 h on a slow shaker. Next, the membranes were immersed in a 1:1000 mouse monoclonal 
Primary Antibody solution (Abcam, Cambridge, MA) in 5 mL blocking buffer with 25 L Tween 
20 (0.05%) on a slow-shaker overnight at 4°C. Antibodies used (Abcam, Cambridge, MA): Anti-
GAPDH antibody [mAbcam 9484] and Anti-Raf1 antibody [RNP1] ab50858. Membranes were 
washed four times on a shaker with PBST for 5 min per wash, to remove any non-specific antibody 
interactions. Membranes were then placed in a 1:10,000 secondary antibody solution (Abcam, 
Cambridge, MA) in 10 mL blocking buffer with 50 L Tween 20 (0.5%) on a slow-shaker for 1 
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hour. Antibody used (LiCor, Lincoln, NE): IRDye 800 CW Goat Anti-Mouse (925-32210). 
Membranes were washed 4 times on a shaker with PBST and once with PBS for 5 min per wash. 
Membranes were immersed in PBS to prevent drying.   Finally, the membranes were imaged with 
the LiCor Odyssey Scanner using the ImageStudio program.  
 
4.9 MAPK/ERK Pathway Experiments 
MAPK/ERK pathway experiments consisted of two key components: CRISPR-Cas9 genomic 
disruption of Raf1 and drug inhibition using Sorafenib Tosylate.  In the macroscale, 0.75 x 105 
cells/mL of H1299 cells were seeded on day 0 in 24-well plates. 600 ng of the pCRISPR plasmid 
targeting eGFP (control) or RAF1 was applied to the wells containing the cells on day 1.  On day 
3, drug conditions were added at different concentrations: 7.5 
which were diluted in complete media.  On day 5, 5 M 
Calcein-AM violet stain (ex = 408 nm and em = 450 nm) diluted in 250 L fresh serum-free 
media was added to the cells and incubated at 37°C for 30 min. The viability of cells was assessed 
by performing a fluorescence well scan using the CLARIOStar well-plate reader. The measured 
fluorescence was normalized to the control to determine the % viability.   
 Similarly, in the microscale, we followed the transfection protocol for seeding cells and the 
7-step protocol for transfection of the pCRISPR plasmid containing sgRNA targeting eGFP or 
Raf-1.  The standard step 7 was replaced with step 7a and step 7b.  In step 7a, Sorafenib Tosylate 
in complete media were actively dispensed into unit droplets and then were diluted with complete 
media to form six different concentrations 7.5 in 
which one droplet (0.7 L was used to passively dispense onto each hydrophilic spot and the other 
droplet was saved for future dilutions.  After all cells were interrogated with the drugs, they were 
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incubated for 2 days.  In step 7b, six unit droplets of 5 Calcein-AM violet stain were passively 
dispensed to the cells and incubated for 30 min in which images were taken to count the cells using 




Chapter 5. Validation of the ACE Platform 
 
This chapter consists of my results and discussion. I will describe the four steps involved 
in developing the ACE platform. First, device and experimental design troubleshooting was 
essential to produce a DMF platform for gene editing. Next, the ACE platform was validated as a 
robust on-demand transfection platform of nucleic acids. Proof-of-concept gene editing was then 
performed by targeted CRISPR-Cas9 gene knock-out of a stably integrated GFP. Finally, the ACE 
platform was demonstrated to hold promise in the identification of cancer genes, by applying it to 
interrogate the MAPK/ERK pathway.  
 
5.1 Device Design: DMF Platform for gene editing 
There has been a wide variety of applications that use gene-editing techniques, particularly those 
involving silencing genes or developing gene therapy techniques related to diseases.135-137 Such 
applications would benefit from a miniaturized automated technique that is capable of integrating 
the gene-editing process on one platform.  Here, we present an automated CRISPR-based 
microfluidic platform that is capable of culturing, editing, and analysing cells.  We call this 
platform “ACE” after the function of this platform – Automated CRISPR Editing.   
The ACE platform was developed to automate the processes related to gene-editing and to 
address the limitations in current techniques to evaluate genes related to a cancer pathway.  ACE 
relies mainly on digital microfluidics (DMF) that will automate the gene-editing processes through 
its versatile liquid handling operations: dispense, merge, mix, and split droplets.  This work builds 
upon several DMF and cell-culture studies that have established proof-of-principle protocols.63, 
138-140 To our knowledge, this is the first DMF-based technique that is capable of cell culturing, 
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gene editing, and image analysis for lung cancer cells, shown in Figure 5.1.  Specifically, this 
platform was tailored to rapidly deliver single-guided RNAs (sgRNA) in an all-in-one pCRISPR 
plasmid format to effectively knockout targeted genes in lung cancer cells.  The device was 
customized with reservoirs for the necessary reagents for lipid-mediated transfection and 
designated regions for incubation, along with a cell culture region to accommodate cell seeding, 
healthy maintenance, and transfection (Figure 5.1).  Genomic disruption can be assessed 
phenotypically on the same device using a microscopy-based imaging analysis workflow to 
determine plasmid delivery efficiencies through monitoring fluorescent protein expression and cell 
viability using various fluorescent dyes. The device comprises of two parallel-plates separated by 
a 140 m spacer.  The bottom-plate consists of metal-patterned electrodes with dielectric and 
hydrophobic layers and serves to manipulate the droplets containing the constituents for gene-
editing.  One of the primary reasons for using DMF in this work is the individual addressability of 
droplets that allows for controlled automated liquid handling on the device.  However, a 
continuous challenge with DMF is the reproducibility of droplet movement on the device, 
especially for liquids that are high in viscosity (e.g., complete cell media).  To alleviate this 
challenge, there are studies that introduce chemical additives or an immiscible fluid to prolong 
droplet movement.53, 141, 142 In this study, one of the primary challenges we initially observed is 
that droplet movement of protein rich solutions (e.g., suspended cells) are difficult to move after 
two days of culturing and maintenance (see Figure 5.2 for designs).  This is problematic given that 
typical gene-editing phenotypic readouts are usually observable beyond two days.  Previous work 
has shown that changing the electrode shape can enhance the driving force of the droplet. 143, 144 
Here, we have modified the electrode design such that the boundary between electrodes are 
interlaced and have added chemical additives in the droplet and observed that droplet movement 
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was improved and completed all the droplet movements necessary (~ 300 total movements for five 
days) for cell culture and maintenance, and gene editing assay.  As described from other studies, 
the primary reason for this improvement could be due to the overlap of the droplet on the adjacent 
electrode which increases the applied force on the droplet and thereby increases the velocity of the 
droplet movement.145 This will minimize the time a droplet is on activated electrode which can 
minimize biofouling on the hydrophobic surface and enable more actuations on the device.  
The top-plate is responsible for adherent cell culture and relies on the microfabrication of 
six 1.5 mm diameter hydrophilic sites. Typically, the cells in suspension are manipulated by 
applying an electric potential. When moved across the hydrophilic spot, a fraction of the droplet 
remains pinned to the hydrophilic spot and will serve as the cell culture microvessel – this 
operation is called “passive dispensing”.146 The delivery of cells to these hydrophilic spots will 
enable cells to adhere, spread, and proliferate in an upside-down configuration (i.e. top plate on 
the bottom).62, 147-149 To prevent evaporation, devices are incubated in a 3D printed humidified 
chamber (Figure 4.6).  After the cells are fixed, the device is flipped to its standard configuration 
and at designated periods, the cells are transfected with CRIPSR-based plasmids that are 
complexed in lipid vesicles for efficient delivery of exogenous material to the cells.  As shown in 
Figure 5.3 successful gene-editing in individual cells using our method occur when cells co-
express both the Cas9 and the sgRNA that assemble into a ribonucleoprotein (RNP) complex and 
is delivered to the nucleus for targeted cleavage.  The complex will seek the target sequence, 
complementary to the seed sequence, using the designed sgRNA and will cleave the target DNA 
which results in a double stranded break and ideally causing a knockout.  For downstream analysis, 
the cells are incubated and labeled with a fluorescent dye delivered in liquid media by passive 
dispensing to determine efficiencies of transfection and gene knockout.  Using a custom 3D-
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printed microscope holder (Figure 4.6), images of the top plate containing cells (without 
disassembling the device) are captured which can be analysed by CellProfiler to calculate the 
percentage of transfected or knocked-out cells to the total number of cells.134  There have been 
previous five other studies which have cultured adherent cells with DMF, but this is the first time 
that lung cancer cells have been cultured, edited, and analysed on such a platform.  Using the 
passive dispensing technique, we tested the reproducibility and viability of the lung cancer cells 
on the hydrophilic spots.  A significant amount of trial-and-error was required to ensure cells were 
healthy and growing to enable gene-editing.  Factors such as cell seeding density and microwell 
culture volume are critical to the maintenance of the cell viability and morphology on the device. 
Cell densities between 1 – 2 x 106 cells/mL were seeded and maintained over five days by 
exchanging media once per 24 h maintained viable lung cancer cells with appropriate 
morphologies.  Depending on the assay, the seeding densities were altered to ensure cells are ready 
for the experiments.  For example, for transfection optimization, cells were required to be 70-80 
% confluent to ensure optimal transfection and therefore we seeded cells at a higher density – 1.75 
x 106 cells/mL (see Figure 5.4 for gene-editing assay timeline).  For longer term experiments – 
such as knockout experiments which required 5-6 days – cells were seeded at a smaller density to 
achieve the desired confluence for gene editing.  At higher densities > 1.5 x 106 cells/mL, the cells 
reached confluency very quickly, resulting in cell senescence prior to endpoint knock-out 






Figure 5.1 – Schematic of the ACE Device. 
(a) Top-view schematic of a digital microfluidic device used for cell culturing, transfection, gene-
editing, and analysis. (b) Side-view schematic showing adherent cells culture on the top-plate.  
The cells are transfected using lipid-mediated delivery of plasmids and then measured for knockout 






Figure 5.2 – Optimization of chip configuration and electrode design.  
(a) The first design shows a configuration with square electrodes.  (b) The current design is 






Figure 5.3 – Step-by-step CRISPR-Cas9 knock-out process at the cellular level. 
(1) Assembly of DNA-lipid complex, (2) endocytosis, (3) endosomal escape, (4) transduction of 
Cas9 and sgRNA, (5) translation of Cas9 mRNA, (6) Cas9 ribonucleoprotein assembly, (7) nuclear 
localization, (8) double-strand break, (9) DNA repair by non-homologous end joining and 






Figure 5.4 – Timeline showing the process of automated gene-editing on chip. 
In red are the reagents added to the cell culture wells, and in green are the cell processing steps 
– namely, transfection efficiency measurements and outgrowth in well-plates for downstream GFP 






5.2 Platform Validation: Transfection Efficiency 
One of the advantages of digital microfluidics is its compatibility with external equipment and 
amenability with microscopy techniques for cellular analysis. 53, 132, 150, 151  In this study, 
microscopic imaging is used to analyse transfection and gene knockout of lung cancer cells on a 
DMF platform.  Fluorescence-based imaging is enabled by staining with fluorescent dyes or by 
the integration of fluorescent proteins and the use of reporter genes (e.g., mCherry, GFP) which 
can also help reveal information about cell state, phenotype and possibly provide some valuable 
insight on gene expression.  As shown in Figure 5.5, for each condition, two images (using UV 
and mCherry filters) displaying fluorescently labelled cells are counted, thresholded, and 
overlapped to measure the transfection efficiency.  The simplicity of positioning the top plate on 
the bottom (such that the top plate was adjacent to the objective) is unique to digital microfluidics 
since there is no requirement of moving parts or tubing that may interfere with the imaging.  Figure 
5.6 shows a representative image that displays two overlapped fluorescent-labelled images grown 
on the hydrophilic spot on DMF devices and for comparison, an overlapped image showing lung 
cancer cells grown on standard 24 well-plates.  As shown, the morphologies of the cultured cells 
were similar on both surfaces. 
  
 





Figure 5.6 – mCherry transfection of H1299 cells in well-plates vs. on DMF. 
 
For gene-editing assays, transfection is typically a necessary procedure and the successful delivery 
of sgRNA and Cas9 into cells is critical in producing double-stranded breaks at the target DNA.152 
Lipid-mediated transfection remains popular due to the ease of use and its availability of reagents 
on the market and is usually less harmful than electroporation techniques. 153, 154 One of the factors 
that affects cationic lipid-mediated transfection is the bioavailability of lipids assembled with the 
anionic nucleic acids or to the negatively supercharged proteins, which can be effectively directed 
to and engulfed by a large proportion of target cells.  Concentration of lipid reagents and of nucleic 
acids are essential to maximize transfection efficiency while minimizing cytotoxicity.  Seeking 
validation of our platform for the transfection of nucleic acids, we generated the lipid-DNA 
complexes by encapsulating an mCherry plasmid and delivering it to the cells on-chip to optimize 
transfection and measure the delivery efficiency.  A portion of the experiment is depicted in Figure 
5.7.  Briefly, droplets of diluted lipids and DNA are dispensed, merged, mixed, and incubated.  
The droplet of complexed DNA-lipids is split and one droplet is used for passive dispensing to 








Figure 5.7 – Video sequence depicting the transfection strategy on the ACE platform.  
A video sequence from Supplementary Movie 1 depicting the mixing of lipids and DNA and the 
passive dispensing procedure onto the hydrophilic spot. (i) Dispensing DNA and lipids from 
separate reservoirs and merging both unit droplets, (ii) Mixing of DNA and lipids on a 2 x 2 
electrode array, (iii) Incubation of complexes for 10 min, (iv) preparing the dilution by dispensing 
a droplet of liquid media, (v) 1:1 dilution of lipid complexes in media and (vi) passive dispensing 
of dilute lipids onto the cell culture spot. 
 
We varied the dilutions of lipid complexes in media from 1:1 to 1:10 and determined that 
transfection efficiency is highest (~65 %) when a ratio of 1:1 is delivered to the cells on chip.  Off-
chip manufacturer’s protocols suggest 1:10 ratios as the optimal,155 however, low efficiencies 
(~15%) are observed when this ratio is performed on chip (Figure 5.8).  We additionally conducted 
higher ratios (> 1:10) in well-plates, but observed that this ratio exhibited cytotoxic effects. We 
hypothesize that signs of deterioration may be due to the presence of larger quantities of lipids 
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which may cause toxicity to the cells due to the increase in likelihood in forming higher charge 
ratio complexes.156 While on device, higher ratios are preferred since the lower volumes and cell 
densities require higher lipid complexes to media ratios for transfection to occur.  As shown from 
Figure 5.8 (inset images) and Supplementary Figure 5.9, the morphology of the cells at the 1:1 
ratio is very similar to the 1:10 (and the other ratios) on device and do not show any signs of cell 
detachment or toxicity.  Next, with the optimal ratios for each platform (1:10 in well plates; 1:1 on 
device), we assessed the transfection efficiency 24 to 48 h post-transfection.  
 






Figure 5.9 – Optimization of on-chip transfection by diluting lipid complexes in liquid media.   
Overlapped eGFP and mCherry images show empirical transfection efficiencies for a range of 
different ratios (1:10, 1:8, 1:6, 1:4, 1:2, 1:1).  The 1:1 ratio shows highest transfection efficiency. 
Scale bar = 0.5 mm. 
 
As shown in Figure 5.10, we successfully delivered plasmids encoding mCherry to H1299 cells 
using our device with transfection efficiencies that were highest after 48 h exhibiting ~74.7 %  
6.8 compared to ~45.7 %  5.9 after 24 h.  We also compared on-chip with well-plate techniques 
and observed no significant differences (P > 0.05) in their efficiencies suggesting that DMF is a 





Figure 5.10 – Transfection efficiency of mCherry2-N1 well-plates vs. DMF devices.  






5.3 Proof-of-Concept: Knock-Out of Stably Integrated GFP 
To test the efficacy of our ACE platform of achieving knockout of endogenous gene targets, we 
used H1299 cells that stably express enhanced GFP (eGFP) at the AAVS1 harboring sites, where 
there are no known adverse effects on cells resulting from the inserted DNA fragment.157 This 
allows simple phenotypic readouts of gene knock-out using GFP fluorescence to monitor the 
success of our platform in producing CRISPR-mediated genome editing.  Initially, we performed 
three experiments to test the starting material for transfecting Cas9: (1) directly transfecting the 
Cas9 protein, (2) co-transfecting plasmids encoding Cas9 only and sgRNAs targeting GFP, and 
(3) transfecting an all-in-one pCRISPR plasmid containing both the Cas9 and sgRNA.  transfecting 
the all-in-one pCRISPR plasmid enabled high levels of Cas9 expression in 24 h while protein 
transfection showed low levels at 24 h.  In the Cas9 protein transfected cells, the level of Cas9 
protein peaked at the first measured time point 4 h, then rapidly decreased and is barely detectable 
in the blot after 24 h. 
 
Figure 5.11 – Cas9 protein levels in H1299 cells when transfecting different starting material.   
Lipid-mediated transfection was done using three different starting materials (DNA and protein), 
and lysates were collected at three different time-points (4, 24, and 72 h). Lane (1) shows pure 
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Cas9 protein to assess transfection of RNP complexes.  Lane (2) shows Cas9 expressing plasmid, 
pCas9, to assess co-transfection of pCas9 with an sgRNA plasmid.  Lane (3) shows transfection of 
pCRISPR all-in-one plasmid (Cas9 and sgRNA).  A negative control was transfected with the 
mCherry2-N1 plasmid and the lysate was collected after 24 h. The expected protein size of Cas9 
is 160 kDa which is highlighted in red. 
 
Upon realizing favorable expression patterns of the all-in-one pCRISPR plasmid, we opted for this 
format given the stability of plasmid DNA as opposed to RNA and protein, the guarantee that 
successfully transfected cells co-express both the sgRNA and the Cas9 protein as opposed to co-
transfection, and finally, the ease by which such plasmids are redesigned (Figure 4.1, Figure 4.3).  
For proof-of-concept knock-out experiments, we targeted the GFP and analyzed the knockout 
using a pipeline similar to the transfection pipeline (Figure 5.12-a).  Briefly, a Hoechst stained 
image and a GFP image (Figure 5.12-b) are processed by identifying nuclei and thresholding GFP 
regions – overlapping these images will highlight all the nuclei that are not overlapping GFP-
positive regions, thereby being counted as cells exhibiting GFP knock-out. Comparing the number 
of knock-out nuclei to the total number of nuclei allows for a calculation of GFP knock-out 







Figure 5.12 – Imaging the knockout of stably integrated eGFP. 
(a) A schematic showing the imaging pipeline used for analyzing knockout. (b) An image set 
(Hoechst, GFP, overlap) processed by CellProfiler to assess eGFP knock-out efficiency. 
 
We designed and assembled three pCRISPR plasmids that contain an sgRNA targeting different 
loci in the GFP: upstream (sg_12), middle (sg_497), downstream (sg_683) where the number 
represents the location of the base pairs for targeting (Figure 5.13).  Cells were transfected with a 
larger pCRISPR plasmid (~ 10.5 kb), with a reported transfection efficiency similar to a ~ 5 kb 





Figure 5.13 – eGFP knockout design considerations. 
Plasmid map of the pCRISPR plasmid used showing the transgene integration in NCI-H1299 and 
sgRNA target regions of eGFP. 
 
 
Figure 5.14 – Plot of the transfection efficiency for both the pCRISPR and mCherry2-N1.   
All_in_one_CRISPR/Cas9_LacZ (pCRISPR) has a reporter mCherry gene under an SV40 
promoter, and a CMV promoter was used for the mCherry plasmid. For the transfection, a 1:10 
ratio of lipid complexes to media was used in 24-well plates.  Images of the transfected H1299 




As shown in Figure 5.15, we observed an average efficiency of ~35 % on-chip which is comparable 
to the well-plate experiments ~39 % (P > 0.05).  By analyzing the three different loci, we observe 
the knockout efficiencies for the middle and downstream loci using both technologies are very 
similar.  However, we did observe a difference between the upstream loci (32.8 % vs 47.7 %) 
knockout efficiencies.  We hypothesize that this variation is due to the use of well-plates for cell 
culturing in which adding medium (or any reagent) to the wells can result in uneven distribution, 
attachment, and growth of cells.158  This can cause a high variation in counting the cells using the 
pipeline especially after knockout.  However, we observe that there are no differences in the loci 
(32.8 % for sg_12, 38.5 % for sg_497, and 32.6 % for sg_683) when using DMF and this is 
attributed to the homogeneity and reproducibility of cell culturing on device.62 Therefore, this 
demonstrates the compatibility of DMF for knockout assays related to gene editing.  
 
Figure 5.15 – Plot shown for the GFP knock-out in well-plates compared to the microscale. 
Error bars are ± 1 s.d. from n = 3 with *P < 0.05.   
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5.4 Application: Identification of Cancer Genes in the Ras Pathway 
To evaluate the potential of using our platform for gene editing, we explored the relationship 
between gene function and cell phenotype by studying a cellular signaling pathway. Cellular 
signaling is an intricate process driving various cellular activities such as protein synthesis, cell 
growth and cell senescence, which hold major implications regarding our understanding of tumor 
cell behavior and progression.159 Specifically, the MAPK/ERK (or also known as RAS-RAF-
MEK-ERK) pathway is a highly conserved signaling cascade that plays a crucial role regulating 
cell fate decisions and is often upregulated in human cancers.160, 161 The pathway is depicted in 
Figure 5.16, where a tyrosine receptor kinase serves to relay extracellular signaling to individual 
cells, through mitogen-activation.  RAS and RAF genes are upstream components of the 
MAPK/ERK kinase signaling cascade, and therefore are a nodal point in cell proliferation, flagging 
them as potent oncogenes and natural targets for therapy.  Generally, the RAS protein kinase gets 
phosphorylated and activated and the resulting RAS-GTP will complex with RAF in the plasma 
membrane. The order of subsequent events is still largely unknown, but a series of phosphorylation 
and dephosphorylation enable the dimerization of Raf protein kinases, essential for the catalytic 
activation of RAF.162, 163 Once activated, RAF kinases activate various effector proteins which 
govern cell proliferation.  RAF proteins have been studied for characterization of human cancer – 
notably RAF1 (also known as c-RAF) was the first isoform to be identified as an oncogene, but 
interestingly mutations of RAF1 are rare in human cancers.164 Uncertainties surrounding the 
precise role of RAF1 have driven our interest in studying the effects of disrupting its encoding 
gene.  We initiated this by regulating RAF1 protein expression at both the gene level by CRISPR-






Figure 5.16 – Identification of cancer genes in the Ras pathway. 
Cartoon illustrating signal transduction in the Ras pathway that leads to eventual cell 
proliferation.  The red highlighted boxes show the targeted genes using sgRNAs and the added 










To assess the coupled effects of genome editing and drug inhibition in the macroscale, we 
transfected the H1299 cells with a pCRISPR targeting RAF1 or a control sgRNA and added 15 
M Sorafenib Tosylate on day 2.  Cells with RAF1 gene editing showed a minimum viability of 
~50 % on day 4 over a 7-day experiment (Figure 5.17, Figure 5.18). However, after day 4, cell 
viability levels started to increase while cells interrogated with both pCRISPR and sorafenib 
maintained low basal viability levels (~25 %) after day 4. We hypothesized that this may be due 
to the heterogeneity of the cell population after transfection and knock-out, thereby allowing non-
knocked out cells to continue proliferating.  Evolving the Cas9 enzyme to be more versatile166 or 




Figure 5.17 – Raw data showing absolute fluorescence and the morphology of H1299 cells.   
Four conditions were tested, and microscopy fluorescent images were captured on day 5 using 





Figure 5.18 – Plot showing progression of cell viability over time.  
Four conditions were tested by acquiring fluorescent measurements were over 7 days to assess 
proliferation.  Cells were transfected with either an sgRNA targeting RAF1 or a scramble 
sgRNA, and drug Sorafenib Tosylate or DMSO and was added 48 h post-transfection.  All 







To confirm the effects of targeting RAF1 by genome editing and enzymatic inhibition, 
H1299 cells were cultured, edited, assayed and analysed on the ACE platform following 
procedures for measuring transfection and knockout efficiencies.  Images of the lung cancer cells 
that were transfected with pCRISPR targeting RAF1 and labeled with Calcein-AM were analysed 
using an imaging pipeline (Figure 5.19).  Figure 5.20a (using ACE) shows a dose-response curve 
for Sorafenib Tosylate, illustrating the cell viability of the edited H1299 cells.  We examined the 
effects of RAF protein kinase inhibitor Sorafenib Tosylate with and without CRISPR-mediated 
RAF1 targeting.  For the case with CRISPR-mediated RAF1 targeting, the edited H1299 cells 
showed sensitivity in the linear micromolar range (~7-35 M) upon treatment of sorafenib (similar 
to previous studies168). In addition, the viability of cells decreased compared to the control which 
only targeted eGFP.  Specifically, the fitted dose-response curve based on the sigmoid equation 
revealed that the inhibitory sorafenib concentration achieved half-maximal viability level (IC50) is 
at 7.54 M for the control while there is a ~1.8-fold reduction (13.2 M) when using pCRISPR 
targeting RAF1. An F-test revealed a significant difference between these two curves for 
concentrations between the linear regions of the curve (2.5 – 50 M) (P < 0.05).  These results are 
also verified using well-plates and we observed similar results through fluorescence well-plate 
measurements and microscopy images (Figure 5.20d; see examples of raw data in Figure 5.17). In 
addition, we performed preliminary work to further analyse this result by Western blotting and we 
observed that endogenous RAF1 protein expression was not reduced significantly compared to 
expression in control cells that are transfected with a control pCRISPR (Figure 5.21). We suspect 
that this is due to cell population heterogeneity – to confirm that RAF1 protein expression is 
significantly reduced, we will perform flow cytometry to sort and collect mCherry-positive cells 
(transfected cells) and then reproduce the western blot.  
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The ability to edit genes in cancer cells and to detect a phenotypic response highlights the 




Figure 5.19 – Example of microscopy images used for dose-response curves.   





Figure 5.20 – Dose-response relationships on- and off-chip with relevant GC50. 
 (a) On-chip dose-response curve for H1299 cells transfected with and without individual guides 
targeting Raf-1 at different concentrations of sorafenib. (b)  Off-chip dose-response curve for 
H1299 cells transfected with and without individual guides targeting Raf-1 at different 




Figure 5.21 – Western blot showing probing RAF1 expression levels in H1299 cells 
Three lysates were collected from different tissue culture dishes. (1) Control transfected with a 
control sgRNA and with DMSO vehicle. (2) Transfection of an sgRNA targeting RAF1 and with 










Chapter 6. Concluding Remarks and a Look to the Future 
 
 
In this section, I recapitulate the hallmarks of the thesis and vent the merits of the ACE platform 
as a versatile gene editing platform. In addition, assess the limitations of this work and evaluate 
the future work related to the ACE platform. 
 
6.1 Conclusion 
In this thesis, we report the first demonstration of automated gene editing using digital 
microfluidics with an application to decipher cancer genes.  First, we optimized microfabrication 
procedures related to DMF to accommodate cell culture and gene editing. We characterized the 
integration of gene-editing with DMF in terms of transfection and knockout efficiencies.  We 
optimized and validated our system for transfection efficiency by assessing the expression of an 
mCherry reporter plasmid, comparing it to macroscale results. A new standardized imaging 
pipeline was developed for the first time to analyse transfected cells. Upon realizing favorable 
transfection conditions, we further tailored our ACE platform for directed gene editing using the 
CRISPR-Cas9 system and observed similar transgene (stably integrated GFP) knock-out 
efficiencies to those in the macroscale.  After successful proof-of-concept gene knock-out, we 
demonstrated the functionality of the ACE platform using a gene-editing assay that targets the 
RAF1 gene in the MAPK/ERK pathway. In the process, we highlight the standardized imaging 
pipeline platform, which can be reprogrammed to probe for a wide-range of expression patterns. 
The versatility of the ACE platform is also underlined by integrating a drug inhibition assay related 
to cancer studies. The combination of automation, DMF, and gene-editing presented here provides 
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a basis for future studies that can potentially analyze a wide range of cancer genes. Such a system 
holds great promise in applications related to personalized medicine.  
 
6.2 Future Perspectives 
Digital microfluidics has often been limited by its throughput. However, this limitation can 
be attributed to the immaturity of the technology today. DMF is rapidly evolving, with numerous 
emerging research groups who will serve as frontrunners in the development of HTS using DMF. 
As of today, we can foresee the development of self-contained dynamic microwells and DMF-
operated microtiter plates, that could complement or replace ALHR. This would enable 
independent cell culture and analysis and multiplexed cell-based assays, holding great promise in 
cell proliferation studies and, more broadly, provide great insight into numerous fundamental 
biological processes. Currently, our individual ACE devices harbor six individual microwells, 
which could be seen as a limiting factor. However, now that the platform has been functionally 
tested and validated, we can consider strategies for increased throughput by developing new DMF 
cell culture methods, bypassing the need for top-plate microfabrication and limiting cell culture 
related biofouling. For example, we could tether DMF bottom-plates to standard microtiter top-
plates to culture cells and develop a miniaturized ALHR using DMF. For such developments in 
HTS, we would need robust low-cost devices with optimized surface functionalization to prevent 
biofouling, chemical development of novel surfactants and enhanced automation systems to drive 
perfectly reproducible droplet translation.  
Another area under active investigation today to increase throughput is the use vertical 
interconnects for electrode actuation, which would overcome the design limitations involved in 
wiring individual electrodes. This has been achieved in the past using printed circuit boards 
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(PCBs)169 but the low resolution of PCBs (130 m inter-electrode gap) leads to issues in 
reproducible droplet translation. A solution to this would be to operate DMF using thin-film 
transistors, which would eliminate planar interconnections, reduce the footprint of the controlling 
system and reduce the number of interconnections. Such a solution can be leveraged to create large 
arrays of individually addressable electrodes (e.g. 50 x 50 = 2500 electrodes), thereby allowing 
assays to run in parallel.  Combining this with flow-based microfluidics in a hybrid system could 
also significantly increase throughput. 
Nevertheless, our ACE platform is not as concerned with throughput as other applications 
may be. Upstream bioinformatics and deep learning strategies can narrow down our experimental 
procedures to just a few high probability conditions. Here, we used Benchling for our sgRNA 
design, using a ranking system based on minimizing off-target effects while maximizing on-target 
efficiency. In other words, we performed rational design to plan for our arrayed experiment, by 
selecting the best sgRNA candidate to target the RAF1 gene. The work presented here showcased 
the last step of a potential multi-module gene editing pipeline, where we study the phenotypic 
readout of a gene edit. In the future, we envision a consolidated CRISPR gene editing platform 
streamlining on-demand synthesis of sgRNAs (as double-stranded DNA or as single-stranded 
RNA), with pCRISPR assembly or RNP complex assembly, and downstream transfection and 
analysis. This can be achieved by multiplexing DMF devices by stacking devices and establishing 
fluid communication between individual devices. To my knowledge, such a consolidated CRISPR 
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